Glycosaminoglycans

DBCAT001272Therapeutic category

Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine or N-acetylgalactosamine. A DrugBank category of 23 drugs. 16 of them are approved.

Also known as: Mucopolysaccharides
Drugs: Antithrombin III human
Ardeparin
Bemiparin
Certoparin
Chondroitin sulfate
Cinnamic acid
Dalteparin
Danaparoid
Dermatan sulfate
Diclofenac etalhyaluronate
Dociparstat sodium
Enoxaparin
Heparin
Hyaluronic acid
Hyaluronic acid (non-animal stabilized)
Nadroparin
Parnaparin
Pentosan polysulfate
Reviparin
Roneparstat
Semuloparin
Sevuparin
Tinzaparin

What you can answer from here — as of September 15, 2022

23DrugsEach linked to its full drug card

Listed above

46Drug targetsEvery drug–target pair in the class, with bond type

3,865Marketed productsAcross the regions we cover, with dosage forms and routes

26Routes of administrationHow the drugs in this class are given

Which targets do Glycosaminoglycans share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account